BioSpace News Archive

Ascend, a leading dialysis testing laboratory, U.S. Renal Care, and researchers at Stanford University School of Medicine have completed a study of nearly 5,000 patients receiving dialysis to determine longitudinal antibody-based response and risk for breakthrough infection after SARS-CoV-2 vaccination.

Bristol Myers Squibb announced that Orencia® was approved by the US. FDA for the prophylaxis, or prevention, of acute graft versus host disease, in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.

180 Life Sciences Corp. today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (“Oxford”) for the development and commercialization of HMGB1.

numares Appoints Dr. Gregory Heath As New Member of the Supervisory Board and Submits an Additional Test to the FDA.

Repertoire Immune Medicines, Inc. today announced the appointment of B. Lynne Parshall to its Board of Directors.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to ibrexafungerp for the indication of invasive candidiasis (IC).

Preliminary results of a phase II study of ARAKODA® (tafenoquine) for treatment of mild-moderate COVID-19 disease demonstrate a numerical reduction in the proportion of patients not recovered on Day 14, and that the incidence of drug-related adverse events was low (8.4 percent) and mild, according to 60 Degrees Pharmaceuticals, LLC .

New research in the December 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that only 59% of oncology clinical trials studied provided adequately-defined rules for censoring.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has entered into an exclusive Distribution Agreement with Orpharm LLC (“Orpharm”) for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease, for which there is currently no available treatment or cure.

Speranza Therapeutics announces the launch of an outcomes-based care program for providers treating patients experiencing opioid withdrawal.